Abstract
Isapirone-HCl (5 mg) was administered orally, rectally and locally, by a remote control drug delivery device (HF-capsule) into different segments of the gastrointestinal tract, to four young healthy male adults. The relative systemic bioavailability of the drug from the colon and rectum was 2-3-fold greater than that from the upper gastrointestinal tract. This supports a rationale for a prolonged-release formulation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Borison R. L., Albrecht J. W., Diamond B. I. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull. 1990;26(2):207–210. [PubMed] [Google Scholar]
- Harder S., Fuhr U., Beermann D., Staib A. H. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br J Clin Pharmacol. 1990 Jul;30(1):35–39. doi: 10.1111/j.1365-2125.1990.tb03740.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heller A. H., Beneke M., Kuemmel B., Spencer D., Kurtz N. M. Ipsapirone: evidence for efficacy in depression. Psychopharmacol Bull. 1990;26(2):219–222. [PubMed] [Google Scholar]
- Schechter L. E., Bolaños F. J., Gozlan H., Lanfumey L., Haj-Dahmane S., Laporte A. M., Fattaccini C. M., Hamon M. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther. 1990 Dec;255(3):1335–1347. [PubMed] [Google Scholar]